Engaging Thought Leadership
Over 100 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
Discovery & Development Europe 2025
01 - 02 July 2025 | Basel, Switzerland
Pushing traditional boundaries in pharmaceutical science by accelerating the discovery & development of novel therapeutics
Discovery & Development Europe 2025
Meet Our Expert Speakers
Discovery & Development Europe 2025 again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.
Below are some of our featured speakers:
Dan Hardy
Chief Executive Officer,
Microsol Ltd
Davide Gianni
Senior Director,
AstraZeneca
Emma Mead
Chief Scientific Officer, Oxford Drug Discovery Institute,
University of Oxford
Heinrich Haas
Chief Technology Officer,
Neovacs
Joël Richard
Chief Development Officer,
Enterome
Johan Luthman
Executive Vice President of Research & Development,
Lundbeck
Philippe Marc
Executive Director, Global Head of Integrated Data Sciences,
Novartis
Rekha Lakshmanan
Global Head of Data Office,
AstraZeneca
Sorina Morar-Mitrica
Associate Director Science & Technology,
Novartis
Stephanie Harlfinger
Senior Director, Global Head NCE DMPK,
Merck & Cie KmG
Stephen Pham
Senior Vice President,
Avalyn Pharma Inc.
Yogeshvar Kalia
Prof,
University of Geneva
Afzal R Mohammed
Professor,
Aston University
Andreas Gryczke
Director, Process Engineering,
AbbVie
Andreas Bernkop Schnurch
Professor,
University of Innsbruck
Andrew Woodhead
Head of Chemistry,
Astex Pharmaceuticals
Arne Skerra
Professor,
Technische Universität München
Chuang Kee Ong
Director Data Product,
GSK
Eric Lorent
Senior Scientist,
Sanofi
Farshad Ramazani
Senior Expert Science & Technology,
Novartis Pharma
Giovanni Spagnolli
Chief Technology Officer,
Sibylla Biotech
Holger Kubas
Director Research Pharmaceutics,
Merck US
James Dale
Director of Drug Discovery,
PharmEnable Therapeutics
Jens Twellmeyer
Associate Director Science & Technology,
Novartis AG
Jessica Yu
Senior Scientist,
AstraZeneca
Jörg Berghausen
Associate Director,
Novartis
Juha Monkare
Sr. Scientist,
J&J
Karsten Maeder
Professor,
Martin Luther University Halle-Wittenberg
Knut Biber
Research Fellow & Head of Glial Biology Team,
AbbVie
Manuela Cerina
Scientific Director - Neurodegeneration,
LifeArc
Maria Levitin
Director of RNA Oligonucleotide Delivery, Genetic Medicine,
Grünenthal GmbH
Morten Grunnet
Vice President, Head of Neuroscience,
Lundbeck
Philip Hewitt
Global Head of Early Investigative Toxicology,
Merck
Poppy Winlow
Senior Research Scientist,
AstraZeneca
Preethi Soundarya Sathyamurthi
Senior Scientist,
GSK
Rainer Wilcken
Director, Computational Chemistry,
Flare Therapeutics Inc
Rajaa Sukhun
Senior Director of Research DMPK,
Cytokinetics
Ramesh Kashi
Consultant,
Self Employed
Raul Rodriguez
Vice President,
Woxsen University
Roderick Beijersbergen
Head of NKI Genomics Core Facility & Professor of Functional Genomics,
The Netherlands Cancer Institute
Sabine Kuratli
CMC Lead,
CEPI
Saif Shubber
Associate Director,
Bicycle Therapeutics
Sandor Batkai
Co-founder, Head of Medical Research and Intelligence,
Cardior Pharmaceuticals GmbH
Simone Vecchi
Associate Director - Drug Product Development Scientific Integrator,
Johnson & Johnson Innovative Medicine
Toria Legh-Land
Computational Pharmaceutics Lead,
Microsol
Ulrich Betz
Vice President Innovation Department Head Innovation & Entrepreneurship Incubator,
Merck
Varun Kushwah
Principal Scientist,
RCPE
Vik Reebye
Head of Academic Partnership,
MiNA Therapeutics Ltd
Vincent Acker
Principal Scientist,
Novartis
Vineeta Tripathi
Chief Executive Officer,
Vitarka Therapeutics
Yi Sun
Associate Professor,
Technical University of Denmark
Meet Our Esteemed Sponsors
Platinum Sponsors
Gold Sponsors
Silver Sponsors
NanoFCM
Silver Sponsor
NanoFCM provides a versatile and powerful platform - Flow NanoAnalyzer for the multiparameter analysis of functional nanoparticles (7-500 nm) at single-particle level which has the capacity to measure the size, concentration, and biological properties of nanoparticles. To our knowledge, Flow NanoAnalyzer is the only flow cytometry instrument that covers the size range of exosomes (30-120 nm). Flow NanoAnalyzer is expected to become a powerful tool for life science, nanoscience and nanotechnology studies. Flow NanoAnalyzer can be used for the characterization of extracellular vesicles(EVs), viruses, bacteria, and other natural biological nanoparticles as well as functional nanoparticles, which opens up a window to the nano-world for flow technology. By means of high-selectivity, high-resolution and high-throughput detection of the particle size, concentration, and biochemical properties of a single nanoparticles (7-1000 nm).
Pivot Park Screening Centre
Silver Sponsor
Pivot Park Screening Centre is a Dutch company that offers services in assay development, lab automation, ultra-High Throughput Screening (uHTS), High Content Screening and hit-to-lead profiling, in order to find novel hits for drug development. We develop and miniaturize high-quality cellular, biochemical and biophysical primary, deselection, orthogonal and selectivity assays across various target classes and disease areas, and have carried out over 250 full-deck uHTS campaigns across libraries ranging ~0.3-1.5 million compounds, using label-based and label-free (MALDI-MS) readouts, mostly in 1,536-well plate format. You can either bring your own compound library or use our 300K IP-free druglike compound library.
Bronze Sponsors
.jpg?length=600&name=3d0c22d6-b4ef-4e05-be3b-05fbfbf42619-2-5668375logo-CDDV_L_BLUE_ON_BLUE_SHAD_CMYK-(10).jpg)
InnoCore Pharmaceuticals
Bronze Sponsor
InnoCore Pharmaceuticals is a biopharmaceutical drug delivery company specialized in the development of long acting and minimally invasive drug delivery products for the treatment of several (chronic) diseases e.g. oncology, pain, atherosclerosis, macular degeneration, CV, osteoarthritis. Our company is using a biodegradable polymer based platform for complex injectables by making microspheres, in-situ-forming depo's and implant formulations. We support the formulation of small molecules, peptides and proteins (including antibodies) for controlled release delivery from days up to six months.
Network & Programme Sponsors
.jpg?length=600&name=c8f3ee46-970d-4da4-984f-fe6394fe9ac0-2-5668375logo-Glatt_PS_Mailchimp-header_schmaler-(1).jpg)
Glatt Group
Network & Programme Sponsor
Glatt Pharmaceutical Services offers solutions for formulation and process development of solid dosage forms. Scale up, Clinical trials materials and commercial manufacturing from our sites in Binzen/Germany and Ramsey/New Jersey. We offer clinical supplies management as well as storage and distribution of commercial products from our distribution hub in Lörrach/Germany.
BiomedGPT: Adopting a Generalist Approach to Biomedical AI
BiomedGPT, a versatile AI tool used for biomedical research demonstrated impressive results across a wide range of healthcare tasks.
The Application of RNAi Therapeutics for Cardiovascular Disease Treatment
Alnylam Pharmaceuticals explores the possibility of treating cardiovascular disease with RNAi therapeutics.
Goserelin Acetate – VitalDose® EVA Implant
AI/ML Advancements in Drug Formulation – The Potential of Self-Driving Labs
Intrepid Labs demonstrates how its self-driving lab uses ML and robotics to advance drug formulation.
2024 Nobel Prize in Chemistry Awarded to Pioneering Advances in Protein Design and Structure Prediction
The 2024 Nobel Prize in Chemistry was awarded to three scientists working on computational protein design and protein structure prediction.
Cobenfy: A Critical Breakthrough in Schizophrenia Treatment in Over 30 Years
According to a recent press release, the US FDA has approved Cobenfy, a first-in-class muscarinic agonist developed by Bristol Myers Squibb for the treatment of schizophrenia in adults.
Congress Center Basel
MCH Swiss Exhibition (Basel) Ltd. Messeplatz 21, CH-4058 Basel
By Rail
Basel is an international rail hub with direct ICE, IC and EC connections to Germany, Austria, Italy, France and the Benelux countries. Messe Basel can be reached in five to ten minutes from the three railway stations in Basel: SBB (Switzerland), SNCF (France) (Frankreich) and DB (Badischer Bahnhof, Germany)
By Tram
From the SBB/SNCF railway station, it’s a ten-minute journey on the No. 1 or 2 Tram to the “Messeplatz/Exhibition Square” stop where Messe Basel and the Congress Center are located. From Badischer Bahnhof railway station, “Messeplatz/Exhibition Square” is the second stop on the No. 2 or 6 tram.
By Air
EuroAirport Basel-Mulhouse-Freiburg is 15 minutes by car from Messe Basel. Basel municipal transport’s No. 50 bus additionally provides a straightforward connection from the airport to the SBB/SNCF railway station. From there, tram No. 1 or 2 will take you directly to Messeplatz/Exhibition Square. From Zurich Airport a direct rail connection will bring you to the SBB/SNCF railway station in Basel in less than an hour. For further information including a map and full directions, please visit: https://www.messe-basel.com/en/about-us/getting-to-messe-basel/
By Car
Basel is located at the point where the Swiss, German and French motorway networks all meet. The exhibition and congress site has its own direct link to the A2 motorway. The “Messe” exit will take you straight to the Messe Basel car park with its 1,200 parking spaces.
Oxford Global has secured a number of bedrooms at the Basel Marriott Hotel at a reduced conference rate:
- Monday 30th June 2025 – £265 (Including Breakfast & City Tax)
- Tuesday 1st July 2025 – £265 (Including Breakfast & City Tax)
*Please note: £30 supplement is applicable for double occupancy
Should you wish to book a room, please email help@oxfordglobal.com
The final cut-off date to book bedrooms is Monday 9th June 2025 – any bookings after this date are subject to availability and rates. Please note that any cancellations within 14 days prior to arrival are subject to full cancellation charges.
We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.
As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.
Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.
Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.
If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Discovery & Development Europe 2025 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.
